Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to ne
about
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineKnockdown of EpCAM enhances the chemosensitivity of breast cancer cells to 5-fluorouracil by downregulating the antiapoptotic factor Bcl-2Current status of the prognostic molecular biomarkers in breast cancer: A systematic reviewBoth carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.An interobserver reproducibility analysis of Ki67 visual assessment in breast cancer.Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival.Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese PopulationDesigns of preoperative biomarkers trials in oncology: a systematic review of the literature.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis.The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.Evaluating the benefits and adverse effects of an enthracycline-taxane-capecitabine combined regimen in patients with early breast cancer.Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis.Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer.Assessment of the Ki67 labeling index: a Japanese validation ring study.Ki-67 as a Prognostic Factor in Feline Mammary Carcinoma: What Is the Optimal Cutoff Value?Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.Establishment and Characterization of gc-006-03, a Novel Human Signet Ring Cell Gastric Cancer Cell Line Derived from Metastatic Ascites
P2860
Q26853619-6B005AD4-FC7F-4D62-A541-FBBF3732DD32Q28540713-FE2482EB-E136-4AE5-84D5-8D0037708BFCQ33598494-2EF4886C-51FF-430D-82D1-FDEB72ACD9A9Q34232366-B4E84548-0863-4EAC-9C61-AF20633078B1Q34690824-DA6B564E-6EAD-460C-9DBA-3A1072DD11AAQ35560945-51D9158D-D113-4CE8-9CCA-783F48AFDC81Q35599471-46443E96-AA5E-41B9-BA9C-8958A9D024C9Q36163866-D4F61ACD-40A7-4742-81D7-DEFC14AA32ABQ36653693-F118A80B-4B65-42C8-A806-0EAEB7429F27Q36891801-E4CC479A-7866-4C07-B9DC-E862A1B02198Q38586993-BFE5532F-6D81-4BCC-8B80-06C28C26153CQ38682028-0E417718-3022-4D89-969C-DA95C4E96F1EQ38770344-0F63A39A-2A96-4571-83AB-F681FB06C341Q38771946-115E84A5-3BFF-4427-BB60-B35E872CA883Q44521334-66CF3490-4988-4937-B7CC-F07F6622234FQ47205521-552C67EA-9F81-493A-842C-15EC284C005BQ49169683-CCDD6050-9575-4AB0-9008-56354272BAEEQ49486164-1293A7F0-6262-467A-95CE-382429A1FD87Q50655660-F22283D4-3ADE-4463-ABF6-E2FC2461AA3EQ50690348-45A46B19-2D35-4F64-9E5A-3132CCAA6099Q51015726-81C68F9E-06AE-46A0-AC2F-47B23064EE19Q52628634-C74EA627-FABB-4309-B1F5-6293BE43878CQ57116856-9EC57428-AD74-481C-99DD-6F6D2044B13E
P2860
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to ne
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Randomized trial of preoperati ...... e biomarker for response to ne
@en
Randomized trial of preoperati ...... l– epirubicin–cyclophosphamide
@nl
type
label
Randomized trial of preoperati ...... e biomarker for response to ne
@en
Randomized trial of preoperati ...... l– epirubicin–cyclophosphamide
@nl
prefLabel
Randomized trial of preoperati ...... e biomarker for response to ne
@en
Randomized trial of preoperati ...... l– epirubicin–cyclophosphamide
@nl
P2093
P2860
P1476
Randomized trial of preoperati ...... e biomarker for response to ne
@en
P2093
E Fakhrejahani
F Takahashi
H Yamashita
K Hisamatsu
L W C Chow
P2860
P2888
P356
10.1007/S10549-013-2691-Y
P407
P577
2013-11-01T00:00:00Z